Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zyflamend is a proprietary, multi-herbal dietary supplement developed for pain relief, joint support, and to promote a healthy inflammation response. It is formulated as a blend of ten botanical extracts—rosemary, turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Chinese skullcap. Laboratory studies suggest Zyflamend ingredients possess anti-inflammatory, antiangiogenic, and antiproliferative properties, including inhibition of COX-2 and NF-kappa B pathways. Limited human studies indicate reduction in inflammatory biomarkers (such as C-reactive protein and NF-kappa B levels) and safety in phase I prostate-related clinical trials. The product is marketed as supporting joint function, mobility, flexibility, and general inflammation balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zyflamend.